Literature DB >> 3335916

Tumor uptake as a function of tumor mass: a mathematic model.

L E Williams1, R B Duda, R T Proffitt, B G Beatty, J D Beatty, J Y Wong, J E Shively, R J Paxton.   

Abstract

Inverse correlations of tumor uptake (u), measured in percent injected dose per gram, with tumor mass (m) are demonstrated for phospholipid vesicle, nonspecific and specific monoclonal antibody tracers. Correlation coefficients implied u = B mA in 11 different animal experiments. Experimental exponent (A) values lay in the range -0.28-0.64 with a mean of -0.43 while intercept (B) values varied from 3 to 18. Spherical and cylindrical tumor models implied exponents of -0.33 and -0.5, respectively. Comparison of three implantation sites of the human LS174T xenograft revealed a narrow range of exponents (-0.38- -0.46) indicating a consistent geometry for this tumor. Blood flow to the lesion site and inside its volume (as dictated by tumor size) are factors in tumor uptake. Our results indicate that biodistribution data should include the variation of tumor uptake with mass. For less than 10 g lesions, we predict that radiation absorbed dose will be highly dependent upon tumor size.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335916

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

Authors:  Dhaval K Shah; Lindsay E King; Xiaogang Han; Jo-Ann Wentland; Yanhua Zhang; Judy Lucas; Nahor Haddish-Berhane; Alison Betts; Mauricio Leal
Journal:  AAPS J       Date:  2014-03-01       Impact factor: 4.009

2.  Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.

Authors:  Benjamin Cahan; Lucille Leong; Lawrence Wagman; David Yamauchi; Stephen Shibata; Sharon Wilzcynski; Lawrence E Williams; Paul Yazaki; David Colcher; Paul Frankel; Anna Wu; Andrew Raubitschek; John Shively; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2017-09       Impact factor: 3.099

3.  Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.

Authors:  Jenny Oddstig; Peter Bernhardt; Helena Lizana; Ola Nilsson; Håkan Ahlman; Lars Kölby; Eva Forssell-Aronsson
Journal:  Tumour Biol       Date:  2011-11-23

Review 4.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

Review 5.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

6.  A transition metal complex (Venus flytrap cluster) for radioimmunodetection and radioimmunotherapy.

Authors:  R J Paxton; B G Beatty; M F Hawthorne; A Varadarajan; L E Williams; F L Curtis; C B Knobler; J D Beatty; J E Shively
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass.

Authors:  L E Williams; R B Bares; J Fass; S Hauptmann; V Schumpelick; U Buell
Journal:  Eur J Nucl Med       Date:  1993-04

8.  Targeted radionuclide therapy.

Authors:  Lawrence E Williams; Gerald L DeNardo; Ruby F Meredith
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.